Third Molar SurgeryNCT06720051
Intraosseous Versus Submucosal Dexamethsone Injection in Third Molar Surgery
A study testing Intraosseous dexamethasone injection after 3rd molar surgery and Submucosal dexamethasone injection after 3rd molar surgery in people with Third Molar Surgery, run by Services Institute of Medical Sciences, Pakistan at 1 site in Pakistan.
Trial summary
The goal of this clinical trial is to learn if intraosseous dexamethasone injection is better for pain and swelling postop 3rd molar surgery than submucosal dexamethasone injection. Read more about this study
- Who is it for?
- Ages 18 to 35 years
- Conditions the study is for
- Third Molar Surgery
- What is being tested?
- Intraosseous dexamethasone injection after 3rd molar surgery and Submucosal dexamethasone injection after 3rd molar surgery
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 76 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Jun 2025to 30 Nov 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patients undergoing mandibular third molar surgery
- Age 18 to 35 years
- Male and female
Who cannot join
- Uncontrolled systemic medical problems including diabetes and hypertension
- Presence of any cyst, tumor, or other pathological condition in the molar area
- Presence of any craniofacial anomalies, congenital deformities or syndromes
- Patients with known adverse effects of steroid use
- Previous history of orthodontic treatment
- Have a pain disorder or taking pain medications
- Pregnant and lactating mothers
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site
Services Institute of Medical Sciences Lahore
Lahore, Punjab Province, 54000
Mahreen Mahmood, BDS, 092-3366297558, mahreenmahmood510@gmail.com
Professor Hafiz Aamir Iqbal, 092-3334955789, Haafiz.amer.iqbal@gmail.com
About this study
Official title: Efficacy of Intraosseous Versus Submucosal Dexamethasone Injection in Terms of Pain, Facial Swelling and Interincisal Opening Among Patients Undergoing Third Molar Surgery
The goal of this clinical trial is to learn if intraosseous dexamethasone injection is better for pain and swelling postop 3rd molar surgery than submucosal dexamethasone injection. The main questions it aims to answer are:
Does intraosseous dexamethasone injection provide better pain relief and lessen facial swelling than submucosal dexamethasone injection Does intraosseous dexamethasone injection provide better interincisal opening than submucosal dexamethasone injection Researcher will compare both the techniques to see if intraosseous dexamethasone injection works better than submucosal dexamethasone injection
Read more
Participants will:
Be assessed at 3rd and 7th day postoperatively Pain will be assessed through visual analog scale score Facial measurement will be calculated as horizontal measurement plus vertical measurement divided by 2, where horizontal measurement will be taken as the distance between corner of the mouth and the earlobe attachment, and vertical measurement will be taken as distance from outer canthus of the eye to the angle of jaw.
Interincisal opening will be measured from the incisal edge of the maxillary central incisors to the incisal edge of mandibular central incisors at the midline by using millimeter ruler
Read the detailed description
OBJECTIVE: To determine the efficacy of intraosseous versus submucosal dexamethasone injection in terms of pain, facial swelling and interincisal opening among patients undergoing mandibular 3rd molar surgery OPERATIONAL DEFINITIONS
Mandibular third molar:
A mandibular third molar prevented from erupting into position because of malposition or lack of space will be assessed on clinical (visual examination in oral cavity) and radiographical examination (periapical and/or orthopantomogram) by using Pell and Gregory classification method and modified Winter's classification method
Efficacy:
Efficacy of intraosseous and submucosal dexamethasone will be assessed in terms of lower VAS pain score, less facial swelling, and greater interincisal distance.
Pain:
Pain is an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage. Pain will be assessed using visual analogue scale (VAS), which is a self-administered continuous scale comprised of a line of 10 cm in length, anchored by "no pain (score 0)" and "pain as bad as it could be (score 10)". The patient is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity; and score is determined by measuring the distance between "no pain (score 0)" anchor and the patient's mark. A higher score indicates greater pain intensity
Interincisal opening:
Interincisal opening will be measured from the incisal edge of the maxillary central incisors to the incisal edge of mandibular central incisors at the midline by using millimeter ruler.
Facial swelling:
Facial swelling is the buildup of fluid in the tissues of the face. Facial measurement will be calculated as horizontal measurement plus vertical measurement divided by 2, where horizontal measurement will be taken as the distance between corner of the mouth and the earlobe attachment, and vertical measurement will be taken as distance from outer canthus of the eye to the angle of jaw.
These measurements will be taken as baseline measurement before the procedure, and then on day 3 and 7 after procedure.
HYPOTHESIS:
Intraosseous dexamethasone is more efficacious in terms of pain control, less facial swelling and greater interincisal opening than submucosal dexamethasone among patients undergoing mandibular third molar surgery.
MATERIAL AND METHODS
STUDY DESIGN:
Randomized controlled trial (RCT)
SETTINGS:
Department of Oral \& Maxillofacial Surgery, Services Institute of Medical Sciences, Lahore
DURATION OF STUDY:
Six months after approval of synopsis
SAMPLE SIZE:
A sample size of 76 (38 in each group) calculated using the expected mean difference of pain VAS 0.9 between intraosseous dexamethasone group (3.3±1.3) and submucosal dexamethasone group (2.4±1.1) with 95.0% confidence level and 90.0% power of test.
Formula n = (Zα/2+Zβ)2 * _2 σ2_ d2 Where Zα/2 = Critical value of the normal distribution = 1.96 for 95.0% Cl Zβ = Critical value of the normal distribution = 1.28 for 90.0% power of test σ2 = Population variance = 1.44 d = Difference = 0.9
SAMPLING TECHNIQUE:
Non-probability consecutive sampling technique
DATA COLLECTION PROCEDURE:
The study will be approved by the Institutional Ethics Review Committee of Services Institute of Medical Sciences Lahore. All eligible patients undergoing mandibular third molar surgery will be invited to participate in the study and informed consent will be obtained from all volunteer participants. Total 76 patients (38 in each group) will be randomized into two equal-size groups i.e. Group A and Group B by lottery method. A structured proforma will be used to collect demographic and clinical data.
Before surgery, age, gender, Pell \& Gregory type, Winter's type, baseline interincisal opening and facial measurement will be noted. In Group A, patients will receive 4 mg dexamethasone intraosseous injection into the bone distal to the socket of impacted third molar immediately after extraction of the third molar and before suturing. In Group B, patients will receive 4 mg dexamethasone submucosal injection into the buccal vestibule opposite to the surgical site of impacted third molar immediately after surgery. A team of supervisor and researcher will perform all these procedures. All patients will be prescribed tablet naproxium sodium 550mg twice a day for two days.
Patients will be assessed for pain, interincisal opening and facial measurement at day 3 and 7 after surgery. As per operational definitions, efficacy in terms of lower pain VAS score, less facial swelling, and greater interincisal opening will be compared between intraosseous and submucosal dexamethasone groups.
DATA ANALYSIS PROCEDURE:
Statistical Package for Social Sciences (SPSS) version 27 will be used for data entry and analysis. The quantitative variables such as age, interincisal opening, facial measurement and pain VAS score will be reported using mean ± standard deviation. The qualitative variables such as gender, Pell \& Gregory type, and Winter's type will be reported using number (percent). The comparison between intraosseous and submucosal dexamethasone groups for interincisal opening, facial measurement and pain VAS score will be performed by t-test. The data will be stratified for age and gender. After stratification comparison between intraosseous and submucosal dexamethasone groups for interincisal opening, facial measurement and pain VAS score will be performed by t-test. P-value of ≤0.05 will be considered as significant.
- Conditions
- Third Molar Surgery
- Being tested
- Intraosseous dexamethasone injection after 3rd molar surgery, Submucosal dexamethasone injection after 3rd molar surgery
- Keywords
- intraosseous dexamethasone injection, submucosal dexamethasone injection, Third molar surgery, facial pain in third molar surgery, facial swelling in 3rd molar surgery, interincisal opening in third molar surgery
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intraosseous dexamethasone injection after 3rd molar surgeryProcedure or surgery
In Group A, patients will receive 4 mg dexamethasone intraosseous injection into the bone distal to the socket of impacted third molar immediately after extraction of the third molar and before suturing
Submucosal dexamethasone injection after 3rd molar surgeryProcedure or surgery
In Group B, patients will receive 4 mg dexamethasone submucosal injection into the buccal vestibule opposite to the surgical site of impacted third molar immediately after surgery.
| Study group | Role | What they receive |
|---|---|---|
| Group A will undergo intraosseous dexamethasone injection after 3rd molar surgery | Experimental | In Group A, patients will receive 4 mg dexamethasone intraosseous injection into the bone distal to the socket of impacted third molar immediately after extraction of the third molar and before suturing Receives: Procedure: Intraosseous dexamethasone injection after 3rd molar surgery |
| Group B will undergo submucosal dexamethasone injection after 3rd molar surgery | Active comparator | In Group B, patients will receive 4 mg dexamethasone submucosal injection into the buccal vestibule opposite to the surgical site of impacted third molar immediately after surgery. Receives: Procedure: Submucosal dexamethasone injection after 3rd molar surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain
Pain is an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage. Pain will be assessed using visual analogue scale (VAS), which is a self-administered continuous scale comprised of a line of 10 cm in length, anchored by "no pain (score 0)" and "pain as bad as it could be (score 10)". The patient is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity; and score is determined by measuring the distance between "no pain (score 0)" anchor and the patient's mark. A higher score indicates greater pain intensity
Measured: 3rd and 7th day post operatively
Interincisal opening
Interincisal opening will be measured from the incisal edge of the maxillary central incisors to the incisal edge of mandibular central incisors at the midline by using millimeter ruler
Measured: 3rd and 7th day post operatively
Facial swelling
Facial swelling is the buildup of fluid in the tissues of the face. Facial measurement will be calculated as horizontal measurement plus vertical measurement divided by 2, where horizontal measurement will be taken as the distance between corner of the mouth and the earlobe attachment, and vertical measurement will be taken as distance from outer canthus of the eye to the angle of jaw
Measured: 3rd and 7th day post operatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Dec 2024
- Study start1 Jun 2025 (estimated)
- Primary completion30 Nov 2025 (estimated)
- Study completion30 Nov 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Third Molar SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 76 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Services Institute of Medical Sciences, Pakistan
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Mahreen Mahmood, Services Institute of Medical Sciences, Pakistan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06720051
- Sponsor's protocol ID
- U1111-1315-4156
- Status last verified
- Dec 2024
- First submitted
- 2 Dec 2024
- Last updated
- 13 Dec 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Sirintawat N, Sawang K, Chaiyasamut T, Wongsirichat N. Pain measurement in oral and maxillofacial surgery. J Dent Anesth Pain Med. 2017 Dec;17(4):253-263. doi: 10.17245/jdapm.2017.17.4.253. Epub 2017 Dec 28.
PubMed 29349347
Study at a glance
From the registry record, last updated by the sponsor on 13 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Intraosseous Versus Submucosal Dexamethasone Injection in Terms of Pain, Facial Swelling and Interincisal Opening Among Patients Undergoing Third Molar Surgery
- ClinicalTrials.gov ID
- NCT06720051
- Acronym / sponsor ID
- U1111-1315-4156
- Conditions
- Third Molar Surgery
- Keywords
- intraosseous dexamethasone injection, submucosal dexamethasone injection, Third molar surgery, facial pain in third molar surgery, facial swelling in 3rd molar surgery, interincisal opening in third molar surgery
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 76 participants (estimated)
- Lead sponsor
- Services Institute of Medical Sciences, PakistanOther government
- Study start
- 1 Jun 2025 (estimated)
- Primary completion
- 30 Nov 2025 (estimated)
- Study completion
- 30 Nov 2025 (estimated)
- First posted
- 6 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if intraosseous dexamethasone injection is better for pain and swelling postop 3rd molar surgery than submucosal dexamethasone injection. The main questions it aims to answer are:
Does intraosseous dexamethasone injection provide better pain relief and lessen facial swelling than submucosal dexamethasone injection Does intraosseous dexamethasone injection provide better interincisal opening than submucosal dexamethasone injection Researcher will compare both the techniques to see if intraosseous dexamethasone injection works better than submucosal dexamethasone injection
Participants will:
Be assessed at 3rd and 7th day postoperatively Pain will be assessed through visual analog scale score Facial measurement will be calculated as horizontal measurement plus vertical measurement divided by 2, where horizontal measurement will be taken as the distance between corner of the mouth and the earlobe attachment, and vertical measurement will be taken as distance from outer canthus of the eye to the angle of jaw.
Interincisal opening will be measured from the incisal edge of the maxillary central incisors to the incisal edge of mandibular central incisors at the midline by using millimeter ruler
Detailed description
OBJECTIVE: To determine the efficacy of intraosseous versus submucosal dexamethasone injection in terms of pain, facial swelling and interincisal opening among patients undergoing mandibular 3rd molar surgery OPERATIONAL DEFINITIONS
Mandibular third molar:
A mandibular third molar prevented from erupting into position because of malposition or lack of space will be assessed on clinical (visual examination in oral cavity) and radiographical examination (periapical and/or orthopantomogram) by using Pell and Gregory classification method and modified Winter's classification method
Efficacy:
Efficacy of intraosseous and submucosal dexamethasone will be assessed in terms of lower VAS pain score, less facial swelling, and greater interincisal distance.
Pain:
Pain is an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage. Pain will be assessed using visual analogue scale (VAS), which is a self-administered continuous scale comprised of a line of 10 cm in length, anchored by "no pain (score 0)" and "pain as bad as it could be (score 10)". The patient is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity; and score is determined by measuring the distance between "no pain (score 0)" anchor and the patient's mark. A higher score indicates greater pain intensity
Interincisal opening:
Interincisal opening will be measured from the incisal edge of the maxillary central incisors to the incisal edge of mandibular central incisors at the midline by using millimeter ruler.
Facial swelling:
Facial swelling is the buildup of fluid in the tissues of the face. Facial measurement will be calculated as horizontal measurement plus vertical measurement divided by 2, where horizontal measurement will be taken as the distance between corner of the mouth and the earlobe attachment, and vertical measurement will be taken as distance from outer canthus of the eye to the angle of jaw.
These measurements will be taken as baseline measurement before the procedure, and then on day 3 and 7 after procedure.
HYPOTHESIS:
Intraosseous dexamethasone is more efficacious in terms of pain control, less facial swelling and greater interincisal opening than submucosal dexamethasone among patients undergoing mandibular third molar surgery.
MATERIAL AND METHODS
STUDY DESIGN:
Randomized controlled trial (RCT)
SETTINGS:
Department of Oral \& Maxillofacial Surgery, Services Institute of Medical Sciences, Lahore
DURATION OF STUDY:
Six months after approval of synopsis
SAMPLE SIZE:
A sample size of 76 (38 in each group) calculated using the expected mean difference of pain VAS 0.9 between intraosseous dexamethasone group (3.3±1.3) and submucosal dexamethasone group (2.4±1.1) with 95.0% confidence level and 90.0% power of test.
Formula n = (Zα/2+Zβ)2 * _2 σ2_ d2 Where Zα/2 = Critical value of the normal distribution = 1.96 for 95.0% Cl Zβ = Critical value of the normal distribution = 1.28 for 90.0% power of test σ2 = Population variance = 1.44 d = Difference = 0.9
SAMPLING TECHNIQUE:
Non-probability consecutive sampling technique
DATA COLLECTION PROCEDURE:
The study will be approved by the Institutional Ethics Review Committee of Services Institute of Medical Sciences Lahore. All eligible patients undergoing mandibular third molar surgery will be invited to participate in the study and informed consent will be obtained from all volunteer participants. Total 76 patients (38 in each group) will be randomized into two equal-size groups i.e. Group A and Group B by lottery method. A structured proforma will be used to collect demographic and clinical data.
Before surgery, age, gender, Pell \& Gregory type, Winter's type, baseline interincisal opening and facial measurement will be noted. In Group A, patients will receive 4 mg dexamethasone intraosseous injection into the bone distal to the socket of impacted third molar immediately after extraction of the third molar and before suturing. In Group B, patients will receive 4 mg dexamethasone submucosal injection into the buccal vestibule opposite to the surgical site of impacted third molar immediately after surgery. A team of supervisor and researcher will perform all these procedures. All patients will be prescribed tablet naproxium sodium 550mg twice a day for two days.
Patients will be assessed for pain, interincisal opening and facial measurement at day 3 and 7 after surgery. As per operational definitions, efficacy in terms of lower pain VAS score, less facial swelling, and greater interincisal opening will be compared between intraosseous and submucosal dexamethasone groups.
DATA ANALYSIS PROCEDURE:
Statistical Package for Social Sciences (SPSS) version 27 will be used for data entry and analysis. The quantitative variables such as age, interincisal opening, facial measurement and pain VAS score will be reported using mean ± standard deviation. The qualitative variables such as gender, Pell \& Gregory type, and Winter's type will be reported using number (percent). The comparison between intraosseous and submucosal dexamethasone groups for interincisal opening, facial measurement and pain VAS score will be performed by t-test. The data will be stratified for age and gender. After stratification comparison between intraosseous and submucosal dexamethasone groups for interincisal opening, facial measurement and pain VAS score will be performed by t-test. P-value of ≤0.05 will be considered as significant.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A will undergo intraosseous dexamethasone injection after 3rd molar surgery | Experimental | Procedure: Intraosseous dexamethasone injection after 3rd molar surgeryIn Group A, patients will receive 4 mg dexamethasone intraosseous injection into the bone distal to the socket of impacted third molar immediately after extraction of the third molar and before suturing |
| Group B will undergo submucosal dexamethasone injection after 3rd molar surgery | Active comparator | Procedure: Submucosal dexamethasone injection after 3rd molar surgeryIn Group B, patients will receive 4 mg dexamethasone submucosal injection into the buccal vestibule opposite to the surgical site of impacted third molar immediately after surgery. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Patients undergoing mandibular third molar surgery
- Age 18 to 35 years
- Male and female
Key exclusion criteria (7 listed)
- Uncontrolled systemic medical problems including diabetes and hypertension
- Presence of any cyst, tumor, or other pathological condition in the molar area
- Presence of any craniofacial anomalies, congenital deformities or syndromes
- Patients with known adverse effects of steroid use
- Previous history of orthodontic treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intraosseous dexamethasone injection after 3rd molar surgeryIn Group A, patients will receive 4 mg dexamethasone intraosseous injection into the bone distal to the socket of impacted third molar immediately after extraction of the third molar and before suturing | Procedure or surgery | Group A will undergo intraosseous dexamethasone injection after 3rd molar surgery |
| Submucosal dexamethasone injection after 3rd molar surgeryIn Group B, patients will receive 4 mg dexamethasone submucosal injection into the buccal vestibule opposite to the surgical site of impacted third molar immediately after surgery. | Procedure or surgery | Group B will undergo submucosal dexamethasone injection after 3rd molar surgery |
Primary outcome
Pain
Time frame: 3rd and 7th day post operatively
Pain is an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage. Pain will be assessed using visual analogue scale (VAS), which is a self-administered continuous scale comprised of a line of 10 cm in length, anchored by "no pain (score 0)" and "pain as bad as it could be (score 10)". The patient is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity; and score is determined by measuring the distance between "no pain (score 0)" anchor and the patient's mark. A higher score indicates greater pain intensity
Interincisal opening
Time frame: 3rd and 7th day post operatively
Interincisal opening will be measured from the incisal edge of the maxillary central incisors to the incisal edge of mandibular central incisors at the midline by using millimeter ruler
Facial swelling
Time frame: 3rd and 7th day post operatively
Facial swelling is the buildup of fluid in the tissues of the face. Facial measurement will be calculated as horizontal measurement plus vertical measurement divided by 2, where horizontal measurement will be taken as the distance between corner of the mouth and the earlobe attachment, and vertical measurement will be taken as distance from outer canthus of the eye to the angle of jaw
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Dec 2024.
- Background: PubMed 29349347Sirintawat N, Sawang K, Chaiyasamut T, Wongsirichat N. Pain measurement in oral and maxillofacial surgery. J Dent Anesth Pain Med. 2017 Dec;17(4):253-263. doi: 10.17245/jdapm.2017.17.4.253. Epub 2017 Dec 28.
- Individual participant dataSharing planned: No
Related trials for Third Molar Surgery
Recruiting
Effect of Alpha-Band Binaural Beats on Stress and Recovery in Third Molar Surgery
Dental Anxiety, Postoperative Pain
Not yet recruiting
Antibacterial Effect and Soft Tissue Healing of Chlorhexidine-Coated Polyglactin 910 Sutures After Impacted Lower Third Molar Surgery
Impacted Third Molar Tooth, Surgical Wound Healing
Recruiting
Virtual Reality to Reduce Anxiety in Adults Having Lower Wisdom Tooth Surgery
Dental Anxiety, Mandibular Third Molar
Recruiting
Comparison of Autologous Tooth and Bovine Xenograft in Periodontal Healing After Mandibular Third Molar Extraction
Periodontal Defects After Third Molar Extraction, Periodontal Disease
Not yet recruiting
Effects of Irrigation Solutions at Different Temperatures Used in Mandibular Third Molar Surgery
Third Molars Extraction, Oral Health-Related Quality of Life
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intraosseous dexamethasone injection after 3rd molar surgery and Submucosal dexamethasone injection after 3rd molar surgery in people with Third Molar Surgery, run by Services Institute of Medical Sciences, Pakistan at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mahreen Mahmood, BDS (092-3319440050, mahreenmahmood510@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain (time frame: 3rd and 7th day post operatively). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06720051, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Dec 2024.